Training and Continuing Education


Welcome to CDERLearn, the web page for educational tutorials offered by the Center for Drug Evaluation and Research (CDER). CDER's primary mission is to make certain that safe and effective drugs are available to the American people. There is, however, a strategic initiative to inform and educate people about the safe use of medicine, the drug regulatory process, the vital role health care professionals play to assist FDA in fulfilling its duties, and many other important issues. Online training is one way to share FDA expertise with many more people than face-to-face classroom sessions would allow, and we will offer additional CDERLearn courses in the future.  

Course List

  • FDA’s Role in Public Health: Drug Efficacy, Safety, Quality, and Beyond disclaimer icon 
    The purpose of this continuing education (CE) course is to educate a national audience of health care providers, industry, and consumers about the basics of the FDA drug regulatory process and the science that supports CDER’s mission. The course will also educate the nation’s health care providers about their role in communicating drug information to their patients. This updated CDERLearn course replaces the former CDERLearn course, "The Past, Present, and Future of Human Drug Regulation." 

  • FDA Overview of Biosimilar Products disclaimer icon  
    This continuing education (CE) course provides an understanding of biological products and biosimilar products and a description of FDA’s general approach to the development and approval of biosimilar products. The target audience for this course is healthcare professionals, including physicians, physician assistants, nurses, nurse practitioners, and pharmacists.

  • CDER Small Business and Industry Education Series
    CDER's Small Business and Industry Assistance Program has developed a series of Web-based courses to educate regulated small pharmaceutical industry. Note that these courses take approximately 1-3 hours to complete.   

    • Best Practices for Communication Between FDA and IND Sponsors During Drug Development 
      The course describes best practices and procedures for timely, transparent, and effective communications between investigational new drug application (IND) sponsors and FDA at critical junctures in drug development. 
    • Overview of the Generic Drug User Fee Amendments of 2012 (GDUFA)
      This course informs the user about the GDUFA requirements and process, and can serve as a resource for better understanding of GDUFA. It addresses the rationale and benefits of GDUFA, the review and fee commitments under GDUFA, the metrics and goals associated with GDUFA, the self-identification process, and the drug master file changes required under GDUFA.
    • GDUFA Self-Identification (SPL) Submission – Part 1
      This course is Part 1 of a two-part web-based training course on GDUFA Self-Identification SPL Submission. The overall goal of this training module is to provide a clearer understanding of mandatory information and its format for self-identification under GDUFA. It offers a comprehensive review of the required data elements and their restrictions for the Self-Identification SPL file.
    • GDUFA Self-Identification (SPL) Submission – Part 2
      This course is Part 2 of a two-part web-based training course on GDUFA Self-Identification SPL Submission.  It focuses on guiding firms through a successful self-identification submission process, including uploading SPL submissions and retrieving acknowledgements.
    • Bringing an Over-the-Counter (OTC) Drug to Market
      The purpose of this course is to provide information on navigating the rules and regulations on bringing an OTC drug to market and the associated FDA processes.
    • Chemistry, Manufacturing, and Controls (CMC) Perspective of the IND
      This course is intended to help IND sponsors become familiar with applicable CMC statutes, regulations, and relevant documents. 
    • Electronic Common Technical Document (eCTD)
      This course provides the essential steps of submitting electronic submissions to CDER, and can serve as a resource for questions about the submission process.
    • Engaging with the FDA During New Drug Development
      This course focuses on familiarizing small pharmaceutical business and industry in general with resources available to communicate with FDA, and provides guidance on effectively interacting with FDA throughout the new drug development process.
    • Human Drug Establishment Registration and Drug Listing Compliance
      This course identifies and discusses the statutory requirements regarding the submission of registration and drug listing information, and provides a clearer understanding of the registration and drug listing process.


  • Case Studies in FDA's Drug Regulatory Processes
    For patients and patient advocacy groups, health professionals, small business, and pharmaceutical and clinical innovators designed to advance knowledge of drug regulatory processes. Each case study promotes active learning through exercises, instructor-led discussions, and quizzes. 

Some courses have been archived. To view them, please see the FDA Archive.


Contact FDA

Toll Free
(855) 543-3784, or
(301) 796-3400
Human Drug Information

Division of Drug Information (CDER)

Office of Communications

Feedback Form

10001 New Hampshire Avenue

Hillandale Building, 4th Floor

Silver Spring, MD 20993

Page Last Updated: 03/31/2017
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English